**TABLE OF CONTENTS**

- Description p.1
- Audience p.2
- Impact Factor p.2
- Abstracting and Indexing p.2
- Editorial Board p.2
- Guide for Authors p.5

**DESCRIPTION**

**Announcement**

From January 2019 *Biomedicine and Pharmacotherapy* will become an open access journal. Authors who publish in Biomedicine and Pharmacotherapy will be able make their work immediately, permanently, and freely accessible. *Biomedicine and Pharmacotherapy* authors will pay an article publishing charge (APC), have a choice of license options, and retain copyright to their published work.

*Biomedicine and Pharmacotherapy* continues with the same aims and scope, editorial team, submission system and rigorous peer review.

*Biomedicine and Pharmacotherapy* authors will pay an article publishing charge (APC), have a choice of license options, and retain copyright to their published work. The APC will be requested after peer review and acceptance and will be required for all accepted articles submitted after 1 November 2018. The APC for Biomedicine and Pharmacotherapy is US$ 2800 (excluding taxes).

**Please note:** Authors who have submitted papers before 1 November 2018 will have their accepted paper published in Biomedicine and Pharmacotherapy at no charge. Authors submitting papers after this date will be requested to pay the APC.

For full information on publishing your paper open access in Biomedicine and Pharmacotherapy, visit the journal's open access page and guide for authors, or visit our FAQs page.

*Biomedicine & Pharmacotherapy* is a multidisciplinary journal which publishes full-length, original research reports, reviews, and preliminary communications or letters to the editor which fall within the general scope of clinical and basic medicine and pharmacology.

The general fields of interest will include Cancer, Nutriceutics, Neurodegenerative, Cardiac and Infectious Diseases.

Special emphasis will be placed on studies of specific topics such as molecular mechanisms, gene regulation in normal and pathologic cells as well as susceptibility in response to oncogenic agents. Effects of drugs on preclinical and clinical pharmacology and the role of bacteria, viruses and parasites in animals and humans.
Brief reports of meetings, symposia and conferences will also be considered for publication as well as brief listings of scientific meetings or academic courses of interest to the readers

AUDIENCE

Hospital practitioners, biologists, pharmacotherapists

IMPACT FACTOR

2017: 3.457 © Clarivate Analytics Journal Citation Reports 2018

ABSTRACTING AND INDEXING

MEDLINE®
SciSearch
BIOSIS/Biological Abstracts
Pascal/INIST-CNRS
Current Contents/Life Sciences
EMBASE/Excerpta Medica
Science Citation Index
ScienceDirect
Elsevier BIOBASE
Scopus
Research4Life (Hinari)

EDITORIAL BOARD

Editor-in-Chief:
D.M. Townsend, Medical University of South Carolina (MUSC), Charleston, South Carolina, USA

Ethics Editor:
K.D. Tew, Medical University of South Carolina (MUSC), Charleston, South Carolina, USA

Executive Editors
A.L. Branco de Barros, Federal University of Minas Gerais, Belo Horizonte, Brazil
S. Desale, Albany Molecular Research Inc (AMRI), Albany, New York, USA
J.D. Gardner, Louisiana State University Health Sciences Center New Orleans, New Orleans, Louisiana, USA
E.N. Maldonado, Medical University of South Carolina, Charleston, South Carolina, USA
D. Rubello, Ospedale Santa Maria della Misericordia, Rovigo, Italy
K.D. Tew, Medical University of South Carolina (MUSC), Charleston, South Carolina, USA
J. Uys, Medical University of South Carolina (MUSC), Charleston, South Carolina, USA
X. Wang, Nanjing Tech University, Nanjing, China
Z. Ye, Medical University of South Carolina (MUSC), Charleston, South Carolina, USA
J. Zhang, Medical University of South Carolina (MUSC), Charleston, South Carolina, USA

Associate Editors:
K. Baek, CHA University, Seongnam, The Republic of Korea
M. J. Barnes, Des Moines University, Des Moines, Iowa, USA
M. M. G. Bini Dutra, Federal University of Minas Gerais, Belo Horizonte, Brazil
J. Bradley, University of the Incarnate Word, San Antonio, Texas, USA
W. C. Chen, Nanjing Medical University, Nanjing, China
D. Cruz-Topete, Louisiana State University Health Sciences Center, Shreveport, Louisiana, USA
I.T.S Da Silva, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil
D. C Ferreira Soares, Itaúba Federal University, Itabira, Brazil
A. Ferretti, Ospedale Santa Maria della Misericordia, Rovigo, Italy
R. Franco Cruz, University of Nebraska at Lincoln, Lincoln, Nebraska, USA
D. Kurtz, Medical University of South Carolina (MUSC), Charleston, South Carolina, USA
E. Leite, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte (MG), Brazil
T. Lerk-suthirat, Mahidol University, Ratchatewi, Bangkok, Thailand
Z. Lin, Tulane University School of Medicine, New Orleans, Louisiana, USA
J. Lu, Southwest University, Chongqing, China
D Lynes, Harvard Medical School, Boston, Massachusetts, USA
Y. M. Ma, University of Mississippi Medical Center, Jackson, Mississippi, USA
F. Maione, University of Naples Federico II, Naples, Italy
L Monte-Neto, FIOCRUZ, Belo Horizonte, Brazil
I. N. Mungrue, Louisiana State University (LSU) Health Sciences Center, New Orleans, Louisiana, USA
S Primeaux, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA
M Queralt-Martin, National Institutes of Health (NIH), Bethesda (MD), Maryland, USA
Y Rao, Zhejiang University, Zhejiang, China
C. Saisawang, Mahidol University, Salaya, Nakhon Pathom, Thailand
S. Saito, Tulane University School of Medicine, New Orleans, Louisiana, USA
M Schwendt, University of Florida, Gainesville, Florida, USA
L. Simon Peter, Louisiana State University Health Sciences Center New Orleans, New Orleans, Louisiana, USA
M. Valentovic, Marshall University, Huntington, West Virginia, USA
S. V Vasconcelos Generoso, Federal University of Minas Gerais, Belo Horizonte, Brazil
K. Velpula, University of Illinois College of Medicine, Peoria, Illinois, USA
J. Womersley, University of Stellenbosch, Stellenbosch, South Africa
X. F. Wu, University of Texas Southwestern Medical Center, Dallas, Texas, USA
A Yabluchanskiy, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA
H. Zhao, Zhejiang Chinese Medical University (ZCMU), Zhejiang, China

Editorial Board:
M.A. Alaoui-Jamali, McGill University, Montréal, Quebec, Canada
A. Aronis, Hebrew University of Jerusalem, Rehovot, Israel
M. Asagiri, Kyoto University, Kyoto, Japan
V. Barak, Hadassah University Medical Center, Jerusalem, Israel
R. Birk, Ariel University, Ariel, Israel
M.-A. Bjornsti, University of Alabama at Birmingham, Birmingham, Alabama, USA
A. Carpi, Università di Pisa, Pisa, Italy
P. Couvreur, Université Paris-Sud (Paris XI), Châtenay-Malabry, France
G. Cyrot, Cabinet médical, Paris, France
M. Djaldeitti, Tel Aviv University, Tel Aviv, Israel
M. Erguchi, Shin-Yamanote Hospital, Tokyo, Japan
W.H. Fridman, Institute des Cordeliers, Paris, France
O. Froy, Hebrew University of Jerusalem, Rehovot, Israel
A. Ganju-Krishan, University of Miami, Miami, Florida, USA
S. Gantsev, Bashkortostan State Medical University, Bashkortostan, Russian Federation
R. Giardino, Instituto Ortopedico Rizzoli, Bologna, Italy
Y. Gu, Nanjing Medical University, Nanjing, China
B. Haendler, Bayer HealthCare AG, Berlin, Germany
Z. He, Hebrew University of Jerusalem, Jerusalem, Israel
H. Jakubowski, Rutgers New Jersey Medical School, Newark, New Jersey, USA
H. Kitasato, Kitasato University School of Medicine, Kanagawa, Japan
D. Kogel, Hospital Rothschild, St-Maur-des-Fossés, France
R. Kohen, Hebrew University of Jerusalem, Jerusalem, Israel
K. Koidem, Aichi Medical University School of Medicine, Nagakute, Japan
N. Kyprianou, University of Kentucky College of Medicine, Lexington, Kentucky, USA
T. Lampidis, University of Miami, Miller School of Medicine, Miami, Florida, USA
J. Lazo, University of Virginia School of Medicine, Charlottesville, Virginia, USA
D. Machover, Hopital Paul Brousse, Paris, France
M. Masatake, Kitasato University School of Medicine, Kanagawa, Japan
E. Monsenego-Ornan, The Hebrew University of Jerusalem, Rehovot, Israel
A. Nicolini, Università di Pisa, Pisa, Italy
G.O. Rankin, Marshall University, Huntington, West Virginia, USA
A. Scalbert, Institut National de la Recherche Agronomique (INRA), Saint-Genes-Champanelle, France
B. Schwartz, Hebrew University of Jerusalem, Rehovot, Israel
Y. Shu, Nanjing University Medical School, Nanjing, China
A. Simopoulos, Center for Genetics, Nutrition and Health, Washington, District of Columbia, USA
O. Tirosh, Hebrew University of Jerusalem, Jerusalem, Israel
M. Toi, Kyoto University, Japan
K. Umezawa, Aichi Medical University School of Medicine, Nagakute, Japan
P. Van Bladeren, Nestlé Research Center, Lausanne 26, Switzerland
M. Yoneda, Aichi Medical University School of Medicine, Nagakute, Japan
J.F. Zagury, Conservatoire National des Arts et Métiers (CNAM), Paris, France

Founding Editors:
Haim Tapiero †
Georges Mathé †
GUIDE FOR AUTHORS

Submission checklist
You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details.

Ensure that the following items are present:

One author has been designated as the corresponding author with contact details:
• E-mail address
• Full postal address

All necessary files have been uploaded:
Manuscript:
• Include keywords
• All figures (include relevant captions)
• All tables (including titles, description, footnotes)
• Ensure all figure and table citations in the text match the files provided
• Indicate clearly if color should be used for any figures in print
Graphical Abstracts / Highlights files (where applicable)
Supplemental files (where applicable)

Further considerations
• Manuscript has been 'spell checked' and 'grammar checked'
• All references mentioned in the Reference List are cited in the text, and vice versa
• Permission has been obtained for use of copyrighted material from other sources (including the Internet)
• A competing interests statement is provided, even if the authors have no competing interests to declare
• Journal policies detailed in this guide have been reviewed
• Referee suggestions and contact details provided, based on journal requirements

For further information, visit our Support Center.

BEFORE YOU BEGIN
Ethics in publishing
Please see our information pages on Ethics in publishing and Ethical guidelines for journal publication.

Studies in humans and animals
If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. The manuscript should be in line with the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals and aim for the inclusion of representative human populations (sex, age and ethnicity) as per those recommendations. The terms sex and gender should be used correctly.

Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

All animal experiments should comply with the ARRIVE guidelines and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, EU Directive 2010/63/EU for animal experiments, or the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) and the authors should clearly indicate in the manuscript that such guidelines have been followed. The sex of animals must be indicated, and where appropriate, the influence (or association) of sex on the results of the study.

Conflict of Interest Policy
The Journal requires full disclosure of all potential conflicts of interest. At the end of the manuscript text, under a subheading "Conflict of Interest statement", all authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. If there are no conflicts of interest, the authors should state: "The authors declare that
there are no conflicts of interest." See also https://www.elsevier.com/conflictsofinterest. A signed Conflict of Interests Policy Form is required upon submission. The corresponding author is responsible for completing the form, and signing it on behalf of all authors.

**Submission declaration and verification**

Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent publication' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service Crossref Similarity Check.

**Preprints**

Please note that preprints can be shared anywhere at any time, in line with Elsevier's sharing policy. Sharing your preprints e.g. on a preprint server will not count as prior publication (see 'Multiple, redundant or concurrent publication' for more information).

**Use of inclusive language**

Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Articles should make no assumptions about the beliefs or commitments of any reader, should contain nothing which might imply that one individual is superior to another on the grounds of race, sex, culture or any other characteristic, and should use inclusive language throughout. Authors should ensure that writing is free from bias, for instance by using 'he or she', 'his/her' instead of 'he' or 'his', and by making use of job titles that are free of stereotyping (e.g. 'chairperson' instead of 'chairman' and 'flight attendant' instead of 'stewardess').

**Changes to authorship**

Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.

Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors after the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

**Copyright**

Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' (see more information on this). Permitted third party reuse of open access articles is determined by the author's choice of user license.

**Author rights**

As an author you (or your employer or institution) have certain rights to reuse your work. More information.

Elsevier supports responsible sharing
Find out how you can share your research published in Elsevier journals.

**Role of the funding source**

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.
**Funding body agreements and policies**

Elsevier has established a number of agreements with funding bodies which allow authors to comply with their funder's open access policies. Some funding bodies will reimburse the author for the gold open access publication fee. Details of existing agreements are available online.

**Open access**

From January 2019, Biomedicine & Pharmacotherapy will move from a subscription to a gold open access publishing model. Authors who publish in Biomedicine & Pharmacotherapy will make their work immediately, permanently, and freely accessible. Authors submitting to the journal on or after November 1, 2018 will be expected to cover the cost of the Article Publishing Charge (APC) to publish in the journal, will have a choice of license options and will retain copyright to their published work.

**Creative Commons Attribution (CC BY)**

Lets others distribute and copy the article, create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), include in a collective work (such as an anthology), text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

**Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)**

For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

The gold open access publication fee for this journal is **USD 2800**, excluding taxes. Learn more about Elsevier's pricing policy: [https://www.elsevier.com/openaccesspricing](https://www.elsevier.com/openaccesspricing).

This journal has an embargo period of 0 months.

**Elsevier Researcher Academy**

[Researcher Academy](https://www.elsevier.com/researcher-academy) is a free e-learning platform designed to support early and mid-career researchers throughout their research journey. The "Learn" environment at Researcher Academy offers several interactive modules, webinars, downloadable guides and resources to guide you through the process of writing for research and going through peer review. Feel free to use these free resources to improve your submission and navigate the publication process with ease.

**Language (usage and editing services)**

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the [English Language Editing service](https://www.elsevier.com/author-support/author-support-services/elsevier-language-editing-service) available from Elsevier's WebShop.

**Submission**

Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

**Submit your article**

Please submit your article via [https://www.evise.com/profile/api/navigate/BIOPHA](https://www.evise.com/profile/api/navigate/BIOPHA)

**Referees**

Please submit the names and institutional e-mail addresses of several potential referees. For more details, visit our [Support site](https://www.elsevier.com/author-support). Note that the editor retains the sole right to decide whether or not the suggested reviewers are used.

**PREPARATION**

**Peer review**

This journal operates a single blind review process. All contributions are typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. [More information on types of peer review](https://www.elsevier.com/author-support/author-support-services/elsevier-language-editing-service).
Use of word processing software

It is important that the file be saved in the native format of the word processor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the word processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier). Note that source files of figures, tables and text graphics will be required whether or not you embed your figures in the text. See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

Article structure

Subdivision - numbered sections

Divide your article into clearly defined and numbered sections. Subsections should be numbered 1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be given a brief heading. Each heading should appear on its own separate line.

Introduction

State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

Material and methods

Provide sufficient details to allow the work to be reproduced by an independent researcher. Methods that are already published should be summarized, and indicated by a reference. If quoting directly from a previously published method, use quotation marks and also cite the source. Any modifications to existing methods should also be described.

Theory/calculation

A Theory section should extend, not repeat, the background to the article already dealt with in the Introduction and lay the foundation for further work. In contrast, a Calculation section represents a practical development from a theoretical basis.

Results

Results should be clear and concise.

Discussion

This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

Conclusions

The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

Appendices

If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.

Essential title page information

• Title. Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
• Author names and affiliations. Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
• Corresponding author. Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.

• Present/permanent address. If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

Highlights
Highlights are a short collection of bullet points that convey the core findings of the article. Highlights are optional and should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point). You can view example Highlights on our information site.

Abstract
A concise and factual abstract is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

Graphical abstract
Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. You can view Example Graphical Abstracts on our information site.

Authors can make use of Elsevier's Illustration Services to ensure the best presentation of their images and in accordance with all technical requirements.

Keywords
Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

Abbreviations
Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

Acknowledgements
Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

Formatting of funding sources
List funding sources in this standard way to facilitate compliance to funder's requirements:

Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].

It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, please include the following sentence:
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Math formulae
Please submit math equations as editable text and not as images. Present simple formulae in line with normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., \(X/Y\). In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by \(\exp\). Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).

Footnotes
Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors can build footnotes into the text, and this feature may be used. Otherwise, please indicate the position of footnotes in the text and list the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.

Artwork
Electronic artwork
General points
- Make sure you use uniform lettering and sizing of your original artwork.
- Embed the used fonts if the application provides that option.
- Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Provide captions to illustrations separately.
- Size the illustrations close to the desired dimensions of the published version.
- Submit each illustration as a separate file.
A detailed guide on electronic artwork is available.

You are urged to visit this site; some excerpts from the detailed information are given here.

Formats
If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format. Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):
- EPS (or PDF): Vector drawings, embed all used fonts.
- TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.
- TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.
- TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.

Please do not:
- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
- Supply files that are too low in resolution;
- Submit graphics that are disproportionately large for the content.

Color artwork
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article. Please indicate your preference for color: in print or online only. Further information on the preparation of electronic artwork.

Illustration services
Elsevier's WebShop offers Illustration Services to authors preparing to submit a manuscript but concerned about the quality of the images accompanying their article. Elsevier's expert illustrators can produce scientific, technical and medical-style images, as well as a full range of charts, tables and graphs. Image 'polishing' is also available, where our illustrators take your image(s) and improve them to a professional standard. Please visit the website to find out more.
Figure captions
Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

Tables
Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

References
Citation in text
Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

Reference links
Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is highly encouraged.

A DOI is guaranteed never to change, so you can use it as a permanent link to any electronic article. An example of a citation using DOI for an article not yet in an issue is: VanDecar J.C., Russo R.M., James D.E., Ambeh W.B., Franke M. (2003). Aseismic continuation of the Lesser Antilles slab beneath northeastern Venezuela. Journal of Geophysical Research, https://doi.org/10.1029/2001JB000884. Please note the format of such citations should be in the same style as all other references in the paper.

Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

Data references
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

Reference management software
Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support Citation Style Language styles, such as Mendeley. Using citation plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide. If you use reference management software, please ensure that you remove all field codes before submitting the electronic manuscript. More information on how to remove field codes from different reference management software.

Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following link:
http://open.mendeley.com/use-citation-style/biomedicine-and-pharmacotherapy
When preparing your manuscript, you will then be able to select this style using the Mendeley plug-ins for Microsoft Word or LibreOffice.

Reference style

Text: Indicate references by number(s) in square brackets in line with the text. The actual authors can be referred to, but the reference number(s) must always be given.
Example: '..... as demonstrated [3,6]. Barnaby and Jones [8] obtained a different result ....'

List: Number the references (numbers in square brackets) in the list in the order in which they appear in the text.

Examples:
Reference to a journal publication:
Reference to a journal publication with an article number:
Reference to a book:
Reference to a chapter in an edited book:
Reference to a website:
Reference to a dataset:

Journal abbreviations source
Journal names should be abbreviated according to the List of Title Word Abbreviations.

Western blots images

Biomedicine & Pharmacotherapy requires submission of the whole uncropped images of the original western blots in triplicate that contributed to the quantitative analysis, from which figures have been derived. Please submit as Supplementary Figure(s). Please note that this is mandatory when western blots are shown.

Video

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the file in one of our recommended file formats with a preferred maximum size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

Research data

This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project.
Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the research data page.

**Data linking**
If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the database linking page.

For supported data repositories a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

**Mendeley Data**
This journal supports Mendeley Data, enabling you to deposit any research data (including raw and processed data, video, code, software, algorithms, protocols, and methods) associated with your manuscript in a free-to-use, open access repository. During the submission process, after uploading your manuscript, you will have the opportunity to upload your relevant datasets directly to Mendeley Data. The datasets will be listed and directly accessible to readers next to your published article online.

For more information, visit the Mendeley Data for journals page.

**Data in Brief**
You have the option of converting any or all parts of your supplementary or additional raw data into one or multiple data articles, a new kind of article that houses and describes your data. Data articles ensure that your data is actively reviewed, curated, formatted, indexed, given a DOI and publicly available to all upon publication. You are encouraged to submit your article for Data in Brief as an additional item directly alongside the revised version of your manuscript. If your research article is accepted, your data article will automatically be transferred over to Data in Brief where it will be editorially reviewed and published in the open access data journal, Data in Brief. Please note an open access fee of 500 USD is payable for publication in Data in Brief. Full details can be found on the Data in Brief website. Please use this template to write your Data in Brief.

**Data statement**
To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the Data Statement page.

**AFTER ACCEPTANCE**

**Online proof correction**
Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors. If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.
We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

Offprints
The corresponding author will, at no cost, receive a customized Share Link providing 50 days free access to the final published version of the article on ScienceDirect. The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's Webshop. Corresponding authors who have published their article gold open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.

AUTHOR INQUIRIES
Visit the Elsevier Support Center to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch.
You can also check the status of your submitted article or find out when your accepted article will be published.

© Copyright 2018 Elsevier | https://www.elsevier.com